Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo

Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advance toward an effective vaccine. A critical step in this process is the activation of naive B cells expressing germline (gl) antibody precursors that have the potential to evolve into bNAbs. Here, we reengineered the BG505 SOSIP.664 glycoprotein to engage gl precursors of bNAbs that target either the trimer apex or the CD4-binding site. The resulting BG505 SOSIP.v4.1-GT1 trimer binds multiple bNAb gl precursors in vitro. Immunization experiments in knock-in mice expressing gl-VRC01 or gl-PGT121 show that this trimer activates B cells in vivo, resulting in the secretion of specific antibodies into the sera. A crystal structure of the gl-targeting trimer at 3.2-Å resolution in complex with neutralizing antibodies 35O22 and 9H+109L reveals a native-like conformation and the successful incorporation of design features associated with binding of multiple gl-bNAb precursors.

• Publication year

  2017

• Venue

  Journal of Experimental Medicine

• Publication date

  2017-09-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1084/jem.20161160PMID 28847869PMCID 5584115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Ig knockin mice to study the development and regulation of HIV‐1 broadly neutralizing antibodies

  2017cited by this paper
• Progress toward active or passive HIV-1 vaccination

  2017cited by this paper
• The HIV‐1 envelope glycoprotein structure: nailing down a moving target

  2017cited by this paper
• Stabilized HIV-1 envelope glycoprotein trimers for vaccine use

  2017influential reference
• Native‐like Env trimers as a platform for HIV‐1 vaccine design

  2017influential reference
• Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development

  2017influential reference
• Germline‐targeting immunogens

  2017influential reference
• A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

  2016cited by this paper
• HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.

  2016cited by this paper
• Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site

  2016cited by this paper
• Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice

  2016cited by this paper
• HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies

  2016influential reference
• Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.

  2016cited by this paper
• Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

  2016influential reference
• Structural basis for germline antibody recognition of HIV-1 immunogens

  2016influential reference
• Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice

  2016influential reference
• Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C

  2016influential reference
• Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein

  2016influential reference
• HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen

  2016cited by this paper
• Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.

  2016cited by this paper
• Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer

  2015cited by this paper
• Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design

  2015cited by this paper
• Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

  2015cited by this paper
• Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.

  2015cited by this paper
• Antibody responses to envelope glycoproteins in HIV-1 infection

  2015cited by this paper
• HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies

  2015influential reference
• HIV-1 neutralizing antibodies induced by native-like envelope trimers

  2015cited by this paper
• Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.

  2015influential reference
• A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene

  2015cited by this paper
• Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

  2015influential reference
• Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.

  2015influential reference
• Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers.

  2015cited by this paper
• Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen

  2015influential reference
• Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

  2014cited by this paper
• Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

  2014cited by this paper
• Structure and immune recognition of trimeric prefusion HIV-1 Env

  2014influential reference
• Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

  2014influential reference
• Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains

  2014cited by this paper
• Structural evolution of glycan recognition by a family of potent HIV antibodies.

  2014cited by this paper
• Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits

  2014influential reference
• Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection

  2014cited by this paper
• HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity

  2013cited by this paper
• Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

  2013influential reference
• Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys

  2013cited by this paper
• Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

  2013influential reference
• Thermodynamic Analysis of the Binding of 2F5 (Fab and Immunoglobulin G Forms) to Its gp41 Epitope Reveals a Strong Influence of the Immunoglobulin Fc Region on Affinity*

  2013cited by this paper
• Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody

  2013cited by this paper
• A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies

  2013influential reference
• HIV‐1 neutralizing antibodies: understanding nature's pathways

  2013cited by this paper
• Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.

  2013cited by this paper
• Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines.

  2013influential reference
• Broadly neutralizing antibodies against HIV-1: templates for a vaccine.

  2013cited by this paper
• Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

  2013influential reference
• Thermodynamic Analysis

  2013cited by this paper
• Antibodies in HIV-1 Vaccine Development and Therapy

  2013influential reference
• Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

  2013cited by this paper
• B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study

  2012influential reference
• Anti-HIV B Cell Lines as Candidate Vaccine Biosensors

  2012cited by this paper
• Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04

  2012cited by this paper
• Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120

  2012cited by this paper
• Rational immunogen design to target specific germline B cell receptors

  2012cited by this paper
• Rational immunogen design to target specific germline B cell receptors

  2012influential reference
• Activity of Broadly Neutralizing Antibodies, Including PG9, PG16, and VRC01, against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Epidemic

  2011cited by this paper
• Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

  2011influential reference
• Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors

  2011influential reference
• Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

  2011cited by this paper
• Broad neutralization coverage of HIV by multiple highly potent antibodies

  2011cited by this paper
• Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

  2011influential reference
• Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01

  2011cited by this paper
• Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

  2010cited by this paper
• Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

  2010cited by this paper
• Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

  2010influential reference
• Few and Far Between: How HIV May Be Evading Antibody Avidity

  2010cited by this paper
• Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

  2010cited by this paper
• Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

  2009cited by this paper
• Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

  2009cited by this paper
• Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies

  2009cited by this paper
• MolProbity: all-atom structure validation for macromolecular crystallography

  2009cited by this paper
• Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

  2009cited by this paper
• Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

  2009influential reference
• Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens

  2009cited by this paper
• The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion

  2008cited by this paper
• Sulfation, the up-and-coming post-translational modification: its role and mechanism in protein-protein interaction.

  2007influential reference
• Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant

  2006cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1

  2003cited by this paper
• Role of antigen receptor affinity in T cell–independent antibody responses in vivo

  2002cited by this paper
• Contrasting IgG structures reveal extreme asymmetry and flexibility.

  2002cited by this paper
• Correspondence e-mail:

  2000influential reference
• Subtypes of Human Immunodeficiency Virus Type 1 and Disease Stage among Women in Nairobi, Kenya

  1999cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997influential reference
• Processing of X-ray diffraction data collected in oscillation mode.

  1997influential reference
• On the use of the merging R factor as a quality indicator for X-ray data

  1997influential reference
• Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification.

  1997cited by this paper
• Binding of autoreactive mouse anti-type II collagen antibodies derived from the primary and the secondary immune response investigated with the biosensor technique.

  1995cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

  1991cited by this paper
• Electronic Reprint Biological Crystallography Phenix : a Comprehensive Python-based System for Macromolecular Structure Solution

  year unknowncited by this paper

• Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors

  2026cites this paper
• Signatures of native-like glycosylation in RNA replicon-derived HIV-1 immunogens.

  2026cites this paper
• Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques

  2025cites this paper
• Simultaneous induction of multiple classes of broadly neutralizing antibody precursors by combination germline-targeting immunization in nonhuman primates.

  2025cites this paper
• Simultaneous priming of HIV broadly neutralizing antibody precursors to multiple epitopes by germline-targeting mRNA-LNP immunogens in mouse models

  2025cites this paper
• From antiretrovirals to curative therapies: Current developments in HIV treatment and prevention.

  2025cites this paper
• GMP Manufacturing and Characterization of the HIV Booster Immunogen HxB2.WT.Core-C4b for Germline Targeting Vaccine Strategies

  2025cites this paper
• A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers

  2025cites this paper
• Novel hydrophobic hyperbranched silicone/graphene-metal oxide nanocomposites for combating marine biofouling

  2025cites this paper
• HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial

  2025cites this paper
• Multiple broadly neutralizing antibody lineages can co-exist and mature in the same germinal centres

  2025cites this paper
• HIV broadly neutralizing antibody precursors to the Apex epitope induced in non-human primates

  2025cites this paper
• Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies

  2025cites this paper
• Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes

  2025influential citation
• Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial

  2025cites this paper
• Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope

  2025cites this paper
• Parallel evolution of the elite neutralizer phenotype in divergent HIV-1 clades

  2025cites this paper
• Yeast Display Reveals Plentiful Mutations That Improve Fusion Peptide Vaccine-Elicited Antibodies Beyond 59% HIV-1 Neutralization Breadth

  2025cites this paper
• The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies

  2025cites this paper
• Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques

  2025cites this paper
• Germline-targeting HIV Envelope SOSIP immunization more frequently elicits broadly-neutralizing antibody precursor responses in infant compared to juvenile rhesus macaques

  2025cites this paper
• Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies

  2025cites this paper
• Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial

  2025cites this paper
• Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design

  2025cites this paper
• Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.

  2025cites this paper
• Precise targeting of human HIV broadly neutralizing antibody precursors

  2025cites this paper
• Diverse priming outcomes under conditions of very rare precursor B cells

  2025cites this paper
• Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-class antibodies

  2025cites this paper
• Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes

  2025influential citation
• CAR-NK cell therapy: a potential antiviral platform.

  2025cites this paper
• Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth

  2025cites this paper
• The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

  2024cites this paper
• Microsecond dynamics control the HIV-1 Envelope conformation

  2024cites this paper
• Diverse priming outcomes under conditions of very rare precursor B cells

  2024cites this paper
• Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.

  2024cites this paper
• Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes

  2024cites this paper
• Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env

  2024cites this paper
• The promise of priming precursors: Advances in inducing CD4 binding site–directed HIV broadly neutralizing antibodies

  2024cites this paper
• Immunization with germ line–targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques

  2024cites this paper
• Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

  2024cites this paper
• Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice

  2024cites this paper
• mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

  2024cites this paper
• mRNA-LNP prime–boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models

  2024cites this paper
• Vaccine priming of rare HIV broadly neutralizing antibody precursors in non-human primates

  2024cites this paper
• Progress on priming HIV-1 immunity

  2024cites this paper
• Diverse competitor B cell responses to a germline-targeting priming immunogen in human Ig loci transgenic mice

  2024influential citation
• Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.

  2024cites this paper
• Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques

  2023cites this paper
• High frequency of HIV precursor-target-specific B cells in sub-Saharan populations

  2023cites this paper
• Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens.

  2023cites this paper
• Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques

  2023cites this paper
• ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’

  2023cites this paper
• Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine

  2023cites this paper
• Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines

  2023cites this paper
• Engaging an HIV vaccine target through the acquisition of low B cell affinity

  2023cites this paper
• Signatures of VH1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins

  2023cites this paper
• Microsecond dynamics control the HIV-1 envelope conformation

  2023cites this paper
• Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions

  2023influential citation
• An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1

  2023cites this paper
• HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design

  2022cites this paper
• High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers

  2022cites this paper
• CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer

  2022cites this paper
• Vaccination induces HIV broadly neutralizing antibody precursors in humans

  2022cites this paper
• Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates

  2022cites this paper
• Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer

  2022cites this paper
• Multivalent display of engineered HIV-1 envelope trimers on silica nanoparticles for targeting and in vitro activation of germline VRC01 B cells.

  2022cites this paper
• Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors

  2022cites this paper
• Use of Transient Transfection for cGMP Manufacturing of eOD-GT8 60mer, a Self-Assembling Nanoparticle Germline-Targeting HIV-1 Vaccine Candidate

  2022cites this paper
• High-resolution structural analysis of enterovirus-reactive polyclonal antibodies in complex with whole virions

  2022influential citation
• Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors

  2022cites this paper
• Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

  2022cites this paper
• Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein

  2022cites this paper
• Comparing methods for immobilizing HIV-1 SOSIPs in ELISAs that evaluate antibody binding

  2022cites this paper
• B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates

  2022cites this paper
• Adjuvants influence the maturation of VRC01-like antibodies during immunization

  2022cites this paper
• Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage

  2022cites this paper
• Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates

  2022cites this paper
• Adjuvants influence the maturation of VRC01-like antibodies during immunization

  2022cites this paper
• Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer

  2022influential citation
• Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies

  2021cites this paper
• High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination

  2021cites this paper
• Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM

  2021cites this paper
• HIV mRNA Vaccines—Progress and Future Paths

  2021cites this paper
• Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells

  2021cites this paper
• Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies

  2021cites this paper
• HIV-1 Envelope Conformation, Allostery, and Dynamics

  2021cites this paper
• Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein

  2021cites this paper
• HIV vaccinology: 2021 update.

  2021cites this paper
• Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens

  2021cites this paper
• Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens

  2021cites this paper
• Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

  2021cites this paper
• Engineering an Antibody V Gene-Selective Vaccine

  2021cites this paper
• The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization

  2021cites this paper
• Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies

  2021cites this paper
• Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.

  2021cites this paper
• Structure‐guided envelope trimer design in HIV‐1 vaccine development: a narrative review

  2021cites this paper
• Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env

  2021cites this paper
• Public Immunity: Evolutionary Spandrels for Pathway-Amplifying Protective Antibodies

  2021cites this paper
• Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions

  2020influential citation
• Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice.

  2020cites this paper